141 related articles for article (PubMed ID: 38434725)
1. Medicare Part B and Part D drug eligibility for center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: estimates using 2016-2019 data.
Qureshi O; Ramachandran R; Ross JS
J Pharm Policy Pract; 2024; 17(1):2312374. PubMed ID: 38434725
[TBL] [Abstract][Full Text] [Related]
2. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
[TBL] [Abstract][Full Text] [Related]
3. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
[TBL] [Abstract][Full Text] [Related]
4. Why Does the Inflation Reduction Act Exclude Expensive Cancer Treatments in Price Negotiations?
Horn DM; Jacobson M; Alpert AE; Duggan MG
JCO Oncol Pract; 2024 Feb; 20(2):254-261. PubMed ID: 38060993
[TBL] [Abstract][Full Text] [Related]
5. Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act.
Vogel M; Kakani P; Chandra A; Conti RM
Nat Biotechnol; 2024 Mar; 42(3):406-412. PubMed ID: 38297186
[TBL] [Abstract][Full Text] [Related]
6. Drugs likely subject to Medicare negotiation, 2026-2028.
Dickson S; Hernandez I
J Manag Care Spec Pharm; 2023 Mar; 29(3):229-235. PubMed ID: 36840960
[No Abstract] [Full Text] [Related]
7. The Inflation Reduction Act: How Will Medicare Negotiating Drug Prices Impact Patients with Heart Disease?
Johnson M; Kishore S; Nayak RK; Dusetzina SB
Curr Cardiol Rep; 2023 Jun; 25(6):577-581. PubMed ID: 37097432
[TBL] [Abstract][Full Text] [Related]
8. Striving for Affordable Medicine: Lessons in Price Negotiation Learned from the United Kingdom.
McKeown MS
J Manag Care Spec Pharm; 2023 Dec; ():1-9. PubMed ID: 38159026
[TBL] [Abstract][Full Text] [Related]
9. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
Odouard IC; Anderson GF; Alexander GC; Ballreich J
J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
[TBL] [Abstract][Full Text] [Related]
10. Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness.
Hernandez I; Cousin EM; Wouters OJ; Gabriel N; Cameron T; Sullivan SD
J Manag Care Spec Pharm; 2024 Mar; 30(3):218-225. PubMed ID: 38088899
[TBL] [Abstract][Full Text] [Related]
11. Cost of Exempting Sole Orphan Drugs From Medicare Negotiation.
Vogel M; Zhao O; Feldman WB; Chandra A; Kesselheim AS; Rome BN
JAMA Intern Med; 2024 Jan; 184(1):63-69. PubMed ID: 38010643
[TBL] [Abstract][Full Text] [Related]
12. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
Dickson S
JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
[TBL] [Abstract][Full Text] [Related]
13. The Constitutionality of Medicare Drug-Price Negotiation under the Takings Clause.
Bhargava R; Brown N; Kapczynski A; Kesselheim AS; Lim SY; Morten CJ
J Law Med Ethics; 2023; 51(4):961-971. PubMed ID: 38477274
[TBL] [Abstract][Full Text] [Related]
14. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
[TBL] [Abstract][Full Text] [Related]
15. Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid.
McCormick N; Wallace ZS; Sacks CA; Hsu J; Choi HK
Arthritis Rheumatol; 2020 Feb; 72(2):234-241. PubMed ID: 31609057
[TBL] [Abstract][Full Text] [Related]
16. Using a patient-centered value assessment to optimize fair prices for Inflation Reduction Act's Medicare Drug Price Negotiation Program.
Poudel N; Ngorsuraches S
J Manag Care Spec Pharm; 2024 Mar; 30(3):241-246. PubMed ID: 38140902
[TBL] [Abstract][Full Text] [Related]
17. The Inflation Reduction Act: A boon for the generic and biosimilar industry.
Niazi SK
J Clin Pharm Ther; 2022 Nov; 47(11):1738-1751. PubMed ID: 36207987
[TBL] [Abstract][Full Text] [Related]
18. Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives.
Hernandez I; Cousin EM; Wouters OJ; Gabriel N; Cameron T; Sullivan SD
J Manag Care Spec Pharm; 2024 Jun; ():1-11. PubMed ID: 38905356
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
20. Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions.
Sullivan SD
Value Health; 2023 Mar; 26(3):394-399. PubMed ID: 36503034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]